Literature DB >> 19060230

Pulmonary epithelium is a prominent source of proteinase-activated receptor-1-inducible CCL2 in pulmonary fibrosis.

Paul F Mercer1, Robin H Johns, Chris J Scotton, Malvina A Krupiczojc, Melanie Königshoff, David C J Howell, Robin J McAnulty, Anuk Das, Andrew J Thorley, Terry D Tetley, Oliver Eickelberg, Rachel C Chambers.   

Abstract

RATIONALE: Studies in patients and experimental animals provide compelling evidence of the involvement of the major thrombin receptor, proteinase-activated receptor-1 (PAR(1)), and the potent chemokine, chemokine (CC motif) ligand-2 (CCL2)/monocyte chemotactic protein-1, in the pathogenesis of idiopathic pulmonary fibrosis (IPF). PAR(1) knockout mice are protected from bleomycin-induced lung inflammation and fibrosis and this protection is associated with marked attenuation in CCL2 induction.
OBJECTIVES: The aim of this study was to determine which cell types represent the major source of PAR(1)-inducible CCL2 in the fibrotic lung.
METHODS: Using immunohistochemistry and dual immunofluorescence, we examined PAR(1) and CCL2 expression in the bleomycin model and human IPF lung. PAR(1) and CCL2 gene expression was also assessed in laser-captured alveolar septae from patients with IPF. The ability of PAR(1) to induce CCL2 production by lung epithelial cells was also examined in vitro.
MEASUREMENTS AND MAIN RESULTS: We report for the first time that PAR(1) and CCL2 are coexpressed and co-up-regulated on the activated epithelium in fibrotic areas in IPF. Similar observations were found in bleomycin-induced lung injury. Furthermore, we show that thrombin is a potent inducer of CCL2 gene expression and protein release by cultured lung epithelial cells via a PAR(1)-dependent mechanism.
CONCLUSIONS: These data support the notion that PAR(1) activation on lung epithelial cells may represent an important mechanism leading to increased local CCL2 release in pulmonary fibrosis. Targeting PAR(1) on the pulmonary epithelium may offer a unique opportunity for therapeutic intervention in pulmonary fibrosis and other inflammatory and fibroproliferative conditions associated with excessive local generation of thrombin and CCL2 release.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19060230      PMCID: PMC2648910          DOI: 10.1164/rccm.200712-1827OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  52 in total

Review 1.  Protease activated receptors: theme and variations.

Authors:  P J O'Brien; M Molino; M Kahn; L F Brass
Journal:  Oncogene       Date:  2001-03-26       Impact factor: 9.867

2.  Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells.

Authors:  Nithiananthan Asokananthan; Peter T Graham; Joshua Fink; Darryl A Knight; Anthony J Bakker; Andrew S McWilliam; Philip J Thompson; Geoffrey A Stewart
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

3.  Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse.

Authors:  H Yasui; E C Gabazza; S Tamaki; T Kobayashi; O Hataji; H Yuda; S Shimizu; K Suzuki; Y Adachi; O Taguchi
Journal:  Am J Respir Crit Care Med       Date:  2001-06       Impact factor: 21.405

4.  Protease-activated receptor 1 and plasminogen activator inhibitor 1 expression in chronic allograft nephropathy: the role of coagulation and fibrinolysis in renal graft fibrosis.

Authors:  G Grandaliano; S Di Paolo; R Monno; G Stallone; E Ranieri; P Pontrelli; L Gesualdo; F P Schena
Journal:  Transplantation       Date:  2001-10-27       Impact factor: 4.939

5.  Protection from pulmonary fibrosis in the absence of CCR2 signaling.

Authors:  B B Moore; R Paine; P J Christensen; T A Moore; S Sitterding; R Ngan; C A Wilke; W A Kuziel; G B Toews
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

6.  Genetic evidence that protease-activated receptors mediate factor Xa signaling in endothelial cells.

Authors:  Eric Camerer; Hiroshi Kataoka; Mark Kahn; Katy Lease; Shaun R Coughlin
Journal:  J Biol Chem       Date:  2002-02-15       Impact factor: 5.157

7.  The dual role of thrombin's anion-binding exosite-I in the recognition and cleavage of the protease-activated receptor 1.

Authors:  T Myles; B F Le Bonniec; S R Stone
Journal:  Eur J Biochem       Date:  2001-01

8.  Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis.

Authors:  D C Howell; N R Goldsack; R P Marshall; R J McAnulty; R Starke; G Purdy; G J Laurent; R C Chambers
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

9.  PAR3 is a cofactor for PAR4 activation by thrombin.

Authors:  M Nakanishi-Matsui; Y W Zheng; D J Sulciner; E J Weiss; M J Ludeman; S R Coughlin
Journal:  Nature       Date:  2000-04-06       Impact factor: 49.962

Review 10.  Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention?

Authors:  R C Chambers
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

View more
  41 in total

Review 1.  Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Authors:  Andrea T Borchers; Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

2.  A macrophage subpopulation recruited by CC chemokine ligand-2 clears apoptotic cells in noninfectious lung injury.

Authors:  Jiurong Liang; Yoosun Jung; Robert M Tighe; Ting Xie; Ningshan Liu; Maura Leonard; Michael Dee Gunn; Dianhua Jiang; Paul W Noble
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-01-27       Impact factor: 5.464

Review 3.  Mechanisms of alveolar epithelial injury, repair, and fibrosis.

Authors:  Rachel C Chambers; Paul F Mercer
Journal:  Ann Am Thorac Soc       Date:  2015-03

4.  Epithelial cells modulate genes associated with NF kappa B activation in co-cultured human macrophages.

Authors:  I Striz; E Brabcova; L Kolesar; X D Liu; I Brabcova; A Sekerkova; J A Poole; M Jaresova; A Slavcev; S I Rennard
Journal:  Immunobiology       Date:  2011-05-01       Impact factor: 3.144

Review 5.  Promising new treatment targets in patients with fibrosing lung disorders.

Authors:  Martina Sterclova; Martina Vasakova
Journal:  World J Clin Cases       Date:  2014-11-16       Impact factor: 1.337

6.  Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis.

Authors:  Resat Cinar; Bernadette R Gochuico; Malliga R Iyer; Tony Jourdan; Tadafumi Yokoyama; Joshua K Park; Nathan J Coffey; Hadass Pri-Chen; Gergő Szanda; Ziyi Liu; Ken Mackie; William A Gahl; George Kunos
Journal:  JCI Insight       Date:  2017-04-20

7.  Molecular insights into the progression of crystalline silica-induced pulmonary toxicity in rats.

Authors:  Rajendran Sellamuthu; Christina Umbright; Jenny R Roberts; Amy Cumpston; Walter McKinney; Bean T Chen; David Frazer; Shengqiao Li; Michael Kashon; Pius Joseph
Journal:  J Appl Toxicol       Date:  2012-03-19       Impact factor: 3.446

Review 8.  Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases.

Authors:  Jens J Posma; Steven P Grover; Yohei Hisada; A Phillip Owens; Silvio Antoniak; Henri M Spronk; Nigel Mackman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-01       Impact factor: 8.311

Review 9.  Pathogenesis of idiopathic pulmonary fibrosis.

Authors:  Paul J Wolters; Harold R Collard; Kirk D Jones
Journal:  Annu Rev Pathol       Date:  2013-09-13       Impact factor: 23.472

10.  Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis.

Authors:  Norihiko Sakai; Andrew M Tager
Journal:  Biochim Biophys Acta       Date:  2013-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.